Drugs / opium
opium
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02502175 | Jun 2017 → Mar 2018 | opiate dependence | University of British Columbia | Completed | Missed primary |
| Phase 3 | NCT00444093 | Mar 2007 → Feb 2008 | cancer, diarrheal disease, enteritis | Philipps University Marburg | Terminated | No outcome recorded Stop: Enrollment |
| Phase 43 trials · 2 missed | ||||||
| Phase 4 | NCT02865395 | Mar 2016 → Jun 2017 | overactive bladder | Campbell Grant | Terminated | No outcome recorded |
| Phase 4 | NCT01150474 | Jan 2011 → Dec 2013 | — | Kristina A. Butler | Completed | Missed primary |
| Phase 4 | NCT01271855 | Jul 2009 → Sep 2011 | — | Loyola University | Completed | Missed primary |
| Phase not applicable2 trials | ||||||
| — | NCT02291042 | Oct 2015 → Feb 2016 | — | Southern New Hampshire Medical Center | Completed | No outcome recorded |
| — | NCT00863928 | Oct 2008 → Jul 2009 | — | Benaroya Research Institute | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT05690321 Comparator | Nov 2022 → Dec 2023 | chronic diarrheal disease | Asbjørn Mohr Drewes | Completed | No outcome recorded |
| Phase 4 | NCT03657407 Comparator | Jun 2016 → May 2017 | — | Anna Reinert | Completed | No outcome recorded |
| Phase 4 | NCT03332056 Comparator | Aug 2013 → Oct 2014 | nephrolithiasis | University of Washington | Completed | No outcome recorded |
| — | NCT05702190 Comparator | Mar 2021 → Jun 2022 | chronic diarrheal disease | Asbjørn Mohr Drewes | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | opium | “The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.” NCT02291042 ↗7“Morphine, the principle agent in opium, binds opioid receptors and blocks ascending pain pathways.” NCT01271855 ↗ “5 drops tincture of opium three times a day” NCT00444093 ↗ |
| Known as | Belladonna and Opium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03332056 ↗ |
| Known as | IDS-NO-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107914 ↗ |
| Known as | Opium tincture | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05690321 ↗ |
| Known as | Papaver somniferum resin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107914 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Being a traditional herbal remedy for pain, OT appears to be a more culturally acceptable alternative to methadone in some parts of Southeast Asia.” NCT02502175 ↗ |
| Route | Other | “Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally” NCT01150474 ↗ |